.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,517,847

« Back to Dashboard

Details for Patent: 6,517,847

Title: Topical gel delivery system
Abstract:A composition is provided that has a viscosity of less than about 15,000 cP and a pH of about 3.0 to 9.0 for treating a skin disorder in a human subject. The composition is a lotion that consists essentially of (a) a therapeutically-effective amount of at least one compound useful for treating such disorder, (b) a pharmaceutically-acceptable, lightly cross-linked polyacrylic acid polymer compatible with the compound, (c) a pharmaceutically acceptable base to adjust pH, (d) up to about 25% ww of at least one water miscible solvent, (e) optionally a preservative, (f) water, and (g) an oil phase component and suitable surfactant. The composition is useful for treating an inflammatory skin disorder, acne, or rosacea.
Inventor(s): Dow; Gordon J. (Santa Rosa, CA), Lathrop; Robert W. (Novato, CA), Dow; Debra A. (Petaluma, CA)
Assignee: Dow Pharmaceutical Sciences (Petaluma, CA)
Filing Date:Mar 08, 2002
Application Number:10/096,516
Claims:1. A composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP for treating a skin disorder in a human subject, which composition consists essentially of (a) a therapeutically-effective amount of at least one compound useful for treating such disorder, (b) a pharmaceutically-acceptable, lightly cross-linked hydrophilic, polyacrylic acid polymer compatible with the compound, (c) a pharmaceutically-acceptable base to adjust pH, (d) up to about 25% w/w of at least one water miscible solvent, (e) optionally a preservative, (f) water, and (g) at least one surfactant in combination with an oil phase sufficient to form a lotion.

2. The composition of claim 1, wherein the compound is an antibiotic, imidazole, retinoid, corticosteroid, or a non-steroidal anti-inflammatory drug (NSAID).

3. The composition of claim 2, wherein the compound is an antibiotic alone or in combination with a corticosteroid or a retinoid.

4. The composition of claim 3, wherein the compound is an antibiotic alone.

5. The composition of claim 3, wherein an antibiotic is combined with a corticosteroid, the antibiotic is clindamycin phosphate, and the corticosteroid is desonide, hydrocortisone valerate, fluocinolone acetonide, hydrocortisone butyrate, or triamcinolone acetonide.

6. The composition of claim 3, wherein an antibiotic is combined with a retinoid, the antibiotic is clindamycin phosphate, and the retinoid is tretinoin.

7. The composition of claim 6 having a pH of about 5 to 6, which composition is a lotion consisting essentially of (a) (i) about 0.5% to about 2.0% w/w clindamycin phosphate and (ii) about 0.01% to about 0.05% w/w tretinoin, (b) about 0. 1% to about 0.5% w/w of the polymer, (c) the base to adjust pH, (d) the water-miscible solvent, (e) less than about 0.2% of a preservative, (f) water, and (g) an oil phase in combination with at least one surfactant to form an emulsion.

8. The composition of claim 2, having a corticosteroid as the sole active agent.

9. The composition of claim 8, wherein the corticosteroid is diflorasone diacetate, fluticasone propionate, halobetasol propionate, budesonide, desonide, betamethasone dipropionate, clobetasol propionate, hydrocortisone butyrate, betamethasone valerate, or fluocinolone acetonide, or triamcinolone acetonide.

10. The composition of claim 1 in combination with a container that accurately administers a portion of the composition for topical administration to a patient.

11. The composition of claim 10 in combination with labeling instructions for use in treating the skin disorder.

12. A method for treating a skin disorder in a human subject, which method comprises topically administering a composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP to an affected area of the subject's skin having such disorder in an amount and for a period of time sufficient to improve the skin disorder, wherein the composition consists essentially of (a) a therapeutically-effective amount of at least one compound useful for treating such disorder, (b) a pharmaceutically-acceptable lightly cross-linked hydrophilic polyacrylic acid polymer compatible with the pharmaceutical active material, (c) a pharmaceutically-acceptable base to adjust pH, (d) up to about 25% w/w of at least one water miscible solvent, (e) optionally a preservative, (f) water, and (g) an oil phase in combination with a surfactant sufficient to form a lotion.

13. The method of claim 12, wherein the skin disorder is an inflammatory skin disorder, acne, or rosacea.

14. The method of claim 13, wherein the composition is administered once a day for the period of time sufficient to improve the skin disorder.

15. The method of claim 14, wherein the compound of the composition is an antibiotic, imidazole, retinoid, corticosteroid, or NSAID.

16. The method of claim 15, wherein the compound is an antibiotic alone or in combination with a corticosteroid, or a retinoid.

17. The method of claim 16, wherein the compound is an antibiotic in combination with a corticosteroid.

18. The method of claim 16, wherein the antibiotic is clindamycin phosphate and is combined with the retinoid tretinoin.

19. The method of claim 18, wherein the composition is a lotion having a pH of about 5 to 6, consisting essentially of (a) (i) about 0.5% to about 2.0% w/w clyndanycin phosphate and (ii) about 0.01% to about 0.05% w/w tretinoin, (b) about 0. 1% to about 0.5% w/w% of the polymer, (c) the base to adjust pH, (d) the water-miscible solvent, (e) less than about 0.2% of a preservative, (f) water, and (g) an oil phase in combination with at least one surfactant to form an emulsion.

20. The method of claim 15, wherein composition contains a corticosteroid as the sole active agent.

21. The method of claim 20, wherein the corticosteroid is diflorasone diacetate, fluticasone propionate, halobetasol propionate, budesonide, desonide, betamethasone dipropionate, clobetasol propionate, hydrocortisone butyrate, betamethasone valerate, fluocinolone acetonide, or triamcinolone acetonide.

22. A method of preparing a composition having a viscosity of less than about 15,000 cP and a pH of about 3 to 9 useful for treating a skin disorder in a human subject, which method comprises (a) combining water and optionally a water miscible solvent with a therapeutically-effective amount of at least one compound useful for treating such disorder and a pharmaceutically-acceptable, lightly cross-linked hydrophilic polyacrylic acid polymer compatible with the compound, (b) adjusting the pH to about 3 to 9, and (c) optionally combining a preservative, a water-miscible solvent (if not included before) and at least one surfactant in combination with an oil phase component to form a lotion.

23. The method of claim 22, wherein the compound is an antibiotic, imidazole, retinoid, corticosteroid, or a NSAID.

24. The method of claim 23, wherein the compound is an antibiotic alone or in combination with a corticosteroid or a retinoid.

25. The method of claim 23, wherein the antibiotic is combined with a corticosteroid, the antibiotic is clindamycin phosphate, and the corticosteroid is desonide, hydrocortisone valerate, fluocinolone acetonide, hydrocortisone butyrate, or triamcinolone acetonide.

26. The method of claim 23, wherein the antibiotic is combined with a retinoid, the antibiotic is clindamycin phosphate, and the retinoid is tretinoin.

27. The method of claim 26, wherein the composition is a lotion having a pH of about 5 to 6 and consists essentially of (a) (i) about 0.5% to about 2.0% w/w clindamycin phosphate and (ii) about 0.010/% to about 0.05% w/w tretinoin, (b) about 0.1% to about 0.5% w/w of the polymer, (c) the base to adjust pH, (d) the water-miscible solvent, (e) less than about 0.2% of a preservative, (f) water, and (g) an oil phase in combination with at least one surfactant to form an emulsion.

28. The method of claim 23, wherein the composition has a corticosteroid as the sole active agent.

29. The method of claim 28, wherein the corticosteroid is diflorasone diacetate, fluticasone propionate, halobetasol propionate, budesonide, desonide betamethasone dipropionate, clobetasol propionate, hydrocortisone butyrate, betamethasone valerate, fluocinolone acetonide, or triamcinolone acetonide.

30. The method of claim 22, which method further comprises placing the composition in a container from which drops are accurately administered for topical administration to a patient.

31. The method of claim 30, which method further comprises combining the container with labeling instructions for use in treating the skin disorder.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc